Phase 3 trial shows no benefit with standard frontline chemotherapy.
ONCOLOGY
Fully funded by 
Content independently selected
-
Nintedanib fails to boost survival in advanced ovarian cancer -
Ovarian cancer: meta-analysis compares primary cytoreduction vs NACT NACT tied to lower morbidity, but no survival advantage in advanced disease.
-
ESMO-ESGO recommendations for early-stage and borderline ovarian cancer Laparotomy for early-stage and fertility-sparing surgery for borderline are recommended.
-
Ovarian cancer: adding HIPEC to surgery is cost-effective Resulting ICER is within the willingness-to-pay threshold in the Netherlands.
-
Cytoreductive surgery for ovarian cancer with high tumour burden Incorporating cytoreductive surgery into the initial management of epithelial ovarian cancer improves survival
-
Ovarian cancer: upfront bevacizumab fails improve overall survival in phase 3 Exploratory analysis suggests survival benefit in BRCA subsets.
-
Niraparib-pembrolizumab shows encouraging activity in recurrent ovarian cancer Phase 1/2 trial of patients with platinum-resistant/refractory disease.
-
Ovarian cancer: maintenance niraparib benefits partial chemotherapy responders Post hoc analysis of phase 3 trial shows benefit regardless of BRCA status.
-
Tubal ligation is not associated with early natural menopause Surgical sterilization is one of the most common methods of contraception in the US.
-
Ovarian cancer: add-on trebananib fails to delay progression in phase 3 Data from the multinational TRINOVA-3 trial.
-
Ovarian cancer: intraperitoneal chemotherapy ineffective in definitive trial Intraperitoneal administration shows no survival advantage, increases toxicity in GOG-252.
-
Niraparib shows activity in heavily pretreated ovarian cancer Phase 2 QUADRA shows benefit extends to HRD-positive platinum-sensitive disease.
-
The study was carried out by the Cancer Research UK Institute at the University of Manchester.
-
LION: lymphadenectomy fails to up OS in advanced ovarian cancer Higher complications were reported after complete macroscopic resection.